SERA · Insider Trading
Sera Prognostics, Inc. Class A Common Stock
Every open-market purchase and sale reported by SERA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Tiffany Eul Davis Inglis | Chief Medical Officer | Sell | −8,024 | −$16.29K |
| 2026-09-11 | Tiffany Eul Davis Inglis | Chief Medical Officer | Sell | −486 | −$972 |
| 2026-09-11 | Zhenya Lindgardt | Chief Executive Officer | Sell | −7,022 | −$14.04K |
| 2026-09-11 | Dyaarl Lee Anderson Jr. | Chief Commercial Officer | Sell | −1,800 | −$3.60K |
| 2026-09-11 | Benjamin Jackson | General Counsel | Sell | −2,190 | −$4.38K |
| 2026-09-09 | Zhenya Lindgardt | Chief Executive Officer | Sell | −20,139 | −$40.28K |
| 2026-09-01 | Scott Gleason | Chief Financial Officer | A | +117,924 | — |
| 2026-07-14 | Mansoor Raza Mirza | Director | A | +24,197 | — |
| 2026-07-14 | Jane F Barlow | Director | A | +24,375 | — |
| 2026-07-14 | Gregory C Critchfield | Director | A | +24,020 | — |
| 2026-07-14 | Joshua Phillips | Director | A | +24,686 | — |
| 2026-07-14 | Sandra AJ Lawrence | Director | A | +24,702 | — |
| 2026-07-14 | Kim P. Kamdar | Director | A | +25,847 | — |
| 2026-07-14 | Mark Christopher Capone | Director | A | +44,379 | — |
| 2026-06-15 | Zhenya Lindgardt | Chief Executive Officer | Sell | −6,990 | −$14.05K |
| 2026-06-15 | Benjamin Jackson | General Counsel | Sell | −2,179 | −$4.38K |
| 2026-06-15 | Dyaarl Lee Anderson Jr. | Chief Commercial Officer | Sell | −4,739 | −$9.53K |
| 2026-06-15 | Austin Aerts | Chief Financial Officer | Sell | −2,037 | −$4.09K |
| 2026-06-15 | Tiffany Eul Davis Inglis | Chief Medical Officer | Sell | −362 | −$728 |
| 2026-06-10 | Austin Aerts | Chief Financial Officer | Sell | −5,440 | −$11.32K |
| 2026-06-10 | Zhenya Lindgardt | Chief Executive Officer | Sell | −20,755 | −$43.17K |
| 2026-06-09 | Sandra AJ Lawrence | Director | Sell | −1,560 | −$3.35K |
| 2026-06-01 | Dyaarl Lee Anderson Jr. | Chief Commercial Officer | A | +3,168 | +$5.83K |
| 2026-06-01 | Benjamin Jackson | General Counsel | A | +5,000 | +$9.20K |
| 2026-03-13 | Zhenya Lindgardt | Chief Executive Officer | A | +154,440 | — |
| 2026-03-13 | Tiffany Eul Davis Inglis | Chief Medical Officer | A | +17,437 | — |
| 2026-03-13 | Austin Aerts | Chief Financial Officer | A | +44,215 | — |
| 2026-03-13 | Benjamin Jackson | General Counsel | A | +44,215 | — |
| 2026-03-13 | Dyaarl Lee Anderson Jr. | Chief Commercial Officer | A | +12,455 | — |
| 2026-03-12 | Robert Gardner Harrison | Chief Information Officer | Sell | −716 | −$1.46K |
| 2026-03-12 | Benjamin Jackson | General Counsel | Sell | −1,027 | −$2.10K |
| 2026-03-12 | John J. Boniface | Chief Scientific Officer | Sell | −1,517 | −$3.09K |
| 2026-03-12 | Paul Kearney | Chief Data Officer | Sell | −1,396 | −$2.85K |
| 2026-03-12 | Austin Aerts | Chief Financial Officer | Sell | −7,088 | −$13.61K |
| 2026-03-12 | Zhenya Lindgardt | Chief Executive Officer | Sell | −25,612 | −$49.08K |
| 2026-03-10 | Austin Aerts | Chief Financial Officer | Sell | −674 | −$1.32K |
| 2026-03-10 | Benjamin Jackson | General Counsel | Sell | −3,119 | −$6.11K |
| 2026-03-10 | Paul Kearney | Chief Data Officer | Sell | −2,026 | −$3.97K |
| 2026-03-10 | Robert Gardner Harrison | Chief Information Officer | Sell | −3,360 | −$6.59K |
| 2026-03-10 | John J. Boniface | Chief Scientific Officer | Sell | −3,038 | −$5.95K |
| 2026-03-06 | Sandra AJ Lawrence | Director | Sell | −1,560 | −$3.04K |
| 2026-02-24 | Robert Gardner Harrison | Chief Information Officer | Sell | −2,000 | −$4.68K |
| 2026-02-04 | Kim P. Kamdar | Director | J | −27,689 | — |
| 2026-01-27 | Robert Gardner Harrison | Chief Information Officer | Sell | −2,000 | −$5.94K |
| 2025-12-30 | Robert Gardner Harrison | Chief Information Officer | Sell | −2,000 | −$6.00K |
| 2025-12-11 | Austin Aerts | Chief Financial Officer | Sell | −873 | −$2.89K |
| 2025-12-11 | John J. Boniface | Chief Scientific Officer | Sell | −1,332 | −$4.41K |
| 2025-12-11 | Zhenya Lindgardt | Chief Executive Officer | Sell | −4,155 | −$13.75K |
| 2025-12-11 | Robert Gardner Harrison | Chief Information Officer | Sell | −616 | −$2.04K |
| 2025-12-11 | Benjamin Jackson | General Counsel | Sell | −892 | −$2.95K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gregory C Critchfield | Chief Executive Officer | 845,292 | $1.72M |
| Zhenya Lindgardt | Chief Executive Officer | 837,848 | $1.71M |
| Austin Aerts | Chief Financial Officer | 301,190 | $614.43K |
| Paul Kearney | Chief Data Officer | 163,961 | $334.48K |
| Benjamin Jackson | General Counsel | 159,566 | $325.51K |
| John J. Boniface | Chief Scientific Officer | 145,842 | $297.52K |
| Scott Gleason | Chief Financial Officer | 117,924 | $240.56K |
| Joshua Phillips | Director | 86,505 | $176.47K |
| Tiffany Eul Davis Inglis | Chief Medical Officer | 83,565 | $170.47K |
| Mansoor Raza Mirza | Director | 80,166 | $163.54K |
| Robert Gardner Harrison | Chief Information Officer | 76,712 | $156.49K |
| Dyaarl Lee Anderson Jr. | Chief Commercial Officer | 76,198 | $155.44K |
| Ryan Trimble | Director | 74,557 | $152.10K |
| Kim P. Kamdar | Director | 54,999 | $112.20K |
| Jane F Barlow | Director | 47,088 | $96.06K |
| Mark Christopher Capone | Director | 44,379 | $90.53K |
| Sandra AJ Lawrence | Director | 38,899 | $79.35K |
| Jeffrey Thomas Elliott | Director | 30,534 | $62.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SERA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.